Comparison of two empiric antibiotic regimen in late onset neonatal sepsis--a randomized controlled trial

Journal of Tropical Pediatrics
Suresh RamasamyBetsy Mathai

Abstract

To compare the effectiveness of two antibiotic regimens among neonates with late onset sepsis (LOS). This randomized controlled trial conducted in a tertiary care teaching hospital, South India, included 90 babies with LOS. Detailed history, examination and appropriate investigations were done for all the babies. Cloxacillin + Amikacin were administered to 40 and Cefotaxime + Gentamicin to 50 babies. Outcomes including mortality, complications and treatment failure were evaluated. Chi-square test was used for categorical variables and Student's unpaired t-test for continuous variables. LOS had a male preponderance, and median time of onset was 13 days. Mortality was more among low birth weight babies irrespective of the antibiotics. Predominant bacteria isolated were coagulase-negative staphylococci (26.67%), Escherichia coli (13.33%) and Streptococcus pneumoniae (13.33%). Complications, mortality and cost were similar in both regimens. There was no significant difference between the two antibiotic regimens with regard to outcome of LOS.

References

Sep 1, 1984·The Journal of Antimicrobial Chemotherapy·I E Haffejee
Feb 25, 2003·Archives of Disease in Childhood. Fetal and Neonatal Edition·D Isaacs, UNKNOWN Australasian Study Group For Neonatal Infections
Sep 6, 2005·Pediatrics·Matthew J BizzarroPatrick G Gallagher
Jun 30, 2010·Archives of Disease in Childhood. Fetal and Neonatal Edition·B Muller-PebodyUNKNOWN iCAP Group (Improving Antibiotic Prescribing in Primary Care)
Oct 1, 2011·The Journal of Maternal-fetal & Neonatal Medicine : the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians·Maisa FeghaliMenachem Miodovnik
Dec 14, 2011·International Journal of Pediatrics·Sindhu SivanandanKamala Swarnam
Sep 14, 2012·The Journal of Maternal-fetal & Neonatal Medicine : the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians·C TziallaM Stronati

❮ Previous
Next ❯

Citations

Jul 5, 2016·The Lancet Infectious Diseases·Laura FolgoriMike Sharland
May 24, 2018·Paediatrics and International Child Health·Aline FuchsJohannes N Van Den Anker
Sep 4, 2016·Neurologia i neurochirurgia polska·A Y MushkinP K Yablonskii
Feb 8, 2020·Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies·Scott L WeissPierre Tissieres
Jul 5, 2018·The Journal of Pediatric Pharmacology and Therapeutics : JPPT : the Official Journal of PPAG·Chad A KnodererKristen R Nichols
May 18, 2021·The Cochrane Database of Systematic Reviews·Steven Kwasi KorangJanus C Jakobsen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Related Papers

Eastern Mediterranean Health Journal = La Revue De Santé De La Méditerranée Orientale = Al-Majallah Al-ṣiḥḥīyah Li-sharq Al-mutawassiṭ
E J K Al-Zwaini
Burns : Journal of the International Society for Burn Injuries
Pia AppelgrenU Ransjö
© 2021 Meta ULC. All rights reserved